Keros Therapeutics, Inc.
NASDAQ:KROS
Overview | Financials
Company Name | Keros Therapeutics, Inc. |
Symbol | KROS |
Currency | USD |
Price | 16.81 |
Market Cap | 680,929,394 |
Dividend Yield | 0% |
52-week-range | 15.67 - 73 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jasbir S. Seehra Ph.D. |
Website | https://www.kerostx.com |
An error occurred while fetching data.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD